SGLT2 inhibitors summarised in new MIMS table

By Chloe Harman on the 30 November 2020

Prescribers can quickly compare key features and benefits of SGLT2 inhibitors for the treatment of type II diabetes using a new MIMS table.

Four SGLT2 inhibitors are available in the UK, all taken as once-daily tablets.

The table summarises costs of SGLT2 inhibitors per 28 days, combinations studied in clinical trials, and recommendations for use in the elderly and patients with hepatic impairment.

Further information

View SGLT2 inhibitor drug records MIMS Diabetes Clinic

Cardiovascular and renal benefits are also covered, including the recently granted approvals for use of SGLT2 inhibitors to treat diabetic kidney disease and symptomatic chronic heart failure.

All four SGLT2 inhibitors - canagliflozin, dapagliflozin, empagliflozin and ertugliflozin - are included, as well as their fixed-dose combinations with metformin and DPP-4 inhibitors.

Information in the table is summarised from manufacturers' summaries of product characteristics.

Available online and in the upcoming December print issue of MIMS, the table can be used alongside the separate MIMS table outlining dose considerations for the use of antidiabetic agents in patients with renal impairment.